Strs Ohio Reduces Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Strs Ohio trimmed its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 762,907 shares of the company’s stock after selling 26,238 shares during the period. Strs Ohio’s holdings in Teva Pharmaceutical Industries were worth $15,411,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth raised its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares during the last quarter. GAMMA Investing LLC raised its holdings in Teva Pharmaceutical Industries by 65.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock valued at $122,000 after acquiring an additional 2,892 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Teva Pharmaceutical Industries by 49.2% during the 2nd quarter. Fifth Third Bancorp now owns 32,805 shares of the company’s stock worth $550,000 after purchasing an additional 10,820 shares during the period. Finally, Hartford Investment Management Co. boosted its holdings in shares of Teva Pharmaceutical Industries by 30.9% during the second quarter. Hartford Investment Management Co. now owns 13,796 shares of the company’s stock worth $231,000 after purchasing an additional 3,257 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent analyst reports. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Barclays began coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target for the company. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Sunday, January 18th. Finally, Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $33.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 200,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. The trade was a 28.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 622,060 shares of company stock valued at $17,076,965. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $31.83 on Monday. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.42. The firm has a market capitalization of $36.51 billion, a P/E ratio of 53.05, a P/E/G ratio of 1.82 and a beta of 0.66. The business’s 50-day simple moving average is $29.64 and its 200-day simple moving average is $22.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.